The Pediatric infectious disease journal
-
Pediatr. Infect. Dis. J. · Jan 1999
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialReactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
To compare the reactogenicity and immunogenicity of a novel live attenuated measles-mumps-rubella vaccine, SB MMR (Priorix; SmithKline Beecham Biologicals), with a widely used MMR vaccine, Merck MMR (M-M-R II; Merck & Co. Inc). ⋯ When administered as primary vaccination in children in the second year of life, the new SB MMR vaccine has been shown to be superior to a comparator vaccine in terms of local reactogenicity, with equivalent immunogenicity.